The inclusion of CALR mutation subtyping is a direct response to the evolving landscape of MPN patient care where understanding the specific type of CALR mutation can influence treatment ...
Researchers are invited to attend presentations by Bruker experts and learn about modern, state-of-the-art approaches to molecular imaging, proteomics, metabolomics and lipidomics at 2 p.m. on Tuesday ...
MENLO PARK, Calif., Oct. 29, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue ...
Pentixapharm itself is currently preparing a US-centric Phase III pivotal study to obtain marketing authorization for PentixaFor in PA. The work of the NCI/NIDDK will add to the global clinical ...